Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial Combination of Photodynamic Therapy with Verteporfin and Intravitreal Ranibizumab in Subfoveal CNV Due to AMD
2006-004978-27Phase 3Completed
- Sponsor
- Landesklinikum St. Pölten
- Start
- Aug 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab and verteporfin in Subretinal neovascularization, sponsored by Landesklinikum St. Pölten. Primary endpoint: Change in visual acuity at 12 months. Started Aug 2007; status: completed.
02
Drugs
ranibizumabverteporfin
03
Conditions
Subretinal neovascularization
Beyond the preview
Go deeper on 2006-004978-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004978-27.